Five accelerated schedules for the tick-borne encephalitis vaccine FSME-Immun® in last-minute travellers: an open-label, single-centre, randomized controlled pilot trial
Journal of Travel Medicine · 2024
DOI: 10.1093/jtm/taad053 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Travel Medicine, 2024. Verfasst von Nicole Berens-Riha und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium. Hauptthemen laut MEDLINE: Encephalitis, Tick-Borne, Viral Vaccines, Immunization Schedule, Encephalitis Viruses, Tick-Borne. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Institute of Tropical Medicine of Antwerp, Royal Higher Institute for Defense Brussels.
Abstract (Originalsprache)
Background
The purpose of this exploratory study was to evaluate different accelerated tick-borne encephalitis (TBE) vaccine schedules for last-minute travellers.
Methods
In a single-centre, open-label pilot study, 77 TBE-naïve Belgian soldiers were randomized to one of the following five schedules with FSME-Immun®: group 1 (‘classical accelerated’ schedule) received one intramuscular (IM) dose at Day 0 and Day 14, group 2 two IM doses at Day 0, group 3 two intradermal (ID) doses at Day 0, group 4 two ID doses at Day 0 and Day 7 and group 5 two ID doses at Day 0 and Day 14. The last dose(s) of the primary vaccination scheme were given after 1 year: IM (1 dose) or ID (2 doses). TBE virus neutralizing antibodies were measured in a plaque reduction neutralization test (PRNT90 and 50) at Days 0, 14, 21, 28, Months 3, 6, 12 and 12+21 days. Seropositivity was defined as neutralizing antibody titres ≥10.
Results
The median age was 19–19.5 years in each group. Median time to seropositivity up to Day 28 was shortest for PRNT90 in ID-group 4 and for PRNT50 in all ID groups. Seroconversion until Day 28 peaked highest for PRNT90 in ID-group 4 (79%) and for PRNT50 in ID-groups 4 and 5 (both 100%). Seropositivity after the last vaccination after 12 months was high in all groups. Previous yellow fever vaccination was reported in 16% and associated with lower geometric mean titres of TBE-specific antibodies at all-time points. The vaccine was generally well tolerated. However, mild to moderate local reactions occurred in 73–100% of ID compared with 0–38% of IM vaccinations, and persistent discolouration was observed in nine ID vaccinated individuals.
Conclusion
The accelerated two-visit ID schedules might offer a better immunological alternative to the recommended classical accelerated IM schedule, but an aluminium-free vaccine would be preferable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
- Centre for Infectious Diseases, Queen Astrid Military Hospital, Brussels, Belgium.
- Department of Internal Medicine and Infectious Diseases, Ghent University Hospital, Belgium.
- Hospital Pharmacy, Queen Astrid Military Hospital, Brussels, Belgium.
- Clinical Laboratory, Queen Astrid Military Hospital, Brussels, Belgium.
Förderung
- Institute of Tropical Medicine of Antwerp
- Royal Higher Institute for Defense Brussels
Zitieren
APA
Berens-Riha, N., Andries, P., Aerssens, A., Ledure, Q., Van Der Beken, Y., Heyndrickx, L., Genbrugge, E., Tsoumanis, A., Van Herrewege, Y., Ariën, K. K., Van Innis, M., Vanbrabant, P., Soentjens, P., & FASTBEPROTECT Research Team (2024). Five accelerated schedules for the tick-borne encephalitis vaccine FSME-Immun® in last-minute travellers: an open-label, single-centre, randomized controlled pilot trial. Journal of Travel Medicine. https://doi.org/10.1093/jtm/taad053
Vancouver
Berens-Riha N, Andries P, Aerssens A, Ledure Q, Van Der Beken Y, Heyndrickx L, et al. Five accelerated schedules for the tick-borne encephalitis vaccine FSME-Immun® in last-minute travellers: an open-label, single-centre, randomized controlled pilot trial. Journal of Travel Medicine. 2024. doi:10.1093/jtm/taad053
BibTeX
@article{BerensRiha2024,
author = {Berens-Riha, Nicole and Andries, Petra and Aerssens, Annelies and Ledure, Quentin and Van Der Beken, Yolien and Heyndrickx, Leo and Genbrugge, Els and Tsoumanis, Achilleas and Van Herrewege, Yven and Ariën, Kevin K and Van Innis, Martine and Vanbrabant, Peter and Soentjens, Patrick and FASTBEPROTECT Research Team, FASTBEPROTECT Research Team},
title = {Five accelerated schedules for the tick-borne encephalitis vaccine FSME-Immun® in last-minute travellers: an open-label, single-centre, randomized controlled pilot trial},
journal = {Journal of Travel Medicine},
year = {2024},
doi = {10.1093/jtm/taad053}
}
EUVIMED